睿知中国医院研究地图
候选清单

正在招募肺癌II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer

ClinicalTrials.gov 上登记的一项肺癌开放试验。牵头方不是本站收录的医院;本站收录的 19 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 19

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 研究中心首都医科大学附属北京胸科医院Beijing Chest Hospital北京医院页面
  2. 研究中心蚌埠医学院第一附属医院First Affiliated Hospital of Bengbu Medical University蚌埠医院页面
  3. 研究中心广州医科大学附属第一医院First Affiliated Hospital of Guangzhou Medical University广州医院页面
  4. 研究中心郑州大学第一附属医院First Affiliated Hospital of Zhengzhou University郑州医院页面
  5. 研究中心中国医科大学附属第一医院First Hospital of China Medical University沈阳医院页面
  6. 研究中心哈尔滨医科大学附属肿瘤医院Harbin Medical University Cancer Hospital哈尔滨医院页面
  7. 研究中心河南省肿瘤医院Henan Cancer Hospital郑州医院页面
  8. 研究中心湖南省肿瘤医院Hunan Cancer Hospital长沙医院页面
  9. 研究中心江苏省人民医院(南医大一附院)Jiangsu Province Hospital南京医院页面
  10. 研究中心吉林省肿瘤医院Jilin Cancer Hospital长春医院页面
  11. 研究中心临沂市肿瘤医院Linyi Cancer Hospital临沂医院页面
  12. 研究中心中国医学科学院肿瘤医院National Cancer Center / Cancer Hospital, CAMS北京医院页面
  13. 研究中心北京协和医院Peking Union Medical College Hospital北京医院页面
  14. 研究中心北京大学肿瘤医院Peking University Cancer Hospital北京医院页面
  15. 研究中心上海市胸科医院Shanghai Chest Hospital上海医院页面
  16. 研究中心上海市肺科医院Shanghai Pulmonary Hospital上海医院页面
  17. 研究中心四川省肿瘤医院Sichuan Cancer Hospital成都医院页面
  18. 研究中心华中科技大学同济医学院附属协和医院Union Hospital武汉医院页面
  19. 研究中心浙江省肿瘤医院Zhejiang Cancer Hospital杭州医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT05168566,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 6

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(6 项)收起清单
  1. 18 岁 至 未注明;性别:不限

    登记记录的入选字段

  2. Confirmation that the tumor harbors a non-resistant uncommon EGFR mutation (tumor tissue biopsy), including one or more of L861Q, G719X and S768I mutations, excluding any other EGFR sensitive mutations and/or oncogenes..

    入选标准第 3 条

  3. Histopathological and/or cytopathological confirmation of locally advanced or metastatic NSCLC patients with ≤ 1 prior line of chemotherapy.

    入选标准第 2 条

    Any systemic anti-tumor therapy such as chemotherapy, and radiation therapy (including curative radiotherapy or spinal radiotherapy portion >30%) used within 3 weeks prior to enrollment; immunotherapy within 4 weeks; any palliative radiotherapy for non-target lesions used to relieve symptoms and traditional Chinese medicines indicated for the tumor (including Chinese patent medicine) within 2 weeks prior to enrollment.

    排除标准第 2 条

    Any unresolved toxicities from prior therapy greater than Grade 1 at the time of screening except alopecia.

    排除标准第 5 条

  4. ECOG score of 0, 1, or 2.

    入选标准第 5 条

  5. Have any other primary malignant tumors within 3 years (except some low- risk cancers).

    排除标准第 18 条

  6. Females who are pregnant or breastfeeding.

    排除标准第 16 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);化验:血常规、肝肾功能;影像与可测量病灶。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT05168566,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Age 18 years old and above, male or female.
  2. Histopathological and/or cytopathological confirmation of locally advanced or metastatic NSCLC patients with ≤ 1 prior line of chemotherapy.
  3. Confirmation that the tumor harbors a non-resistant uncommon EGFR mutation (tumor tissue biopsy), including one or more of L861Q, G719X and S768I mutations, excluding any other EGFR sensitive mutations and/or oncogenes..
  4. At least one measurable lesion.
  5. ECOG score of 0, 1, or 2.
  6. A minimum life expectancy of > 3 months.
  7. Adequate bone marrow reserve, hepatic, renal and coagulation function.
  8. Willingness of all subjects of childbearing potential to use acceptable methods of birth control.

排除标准:Exclusion Criteria:

  1. Ever used the epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) for anti-tumor therapy prior to enrollment.
  2. Any systemic anti-tumor therapy such as chemotherapy, and radiation therapy (including curative radiotherapy or spinal radiotherapy portion >30%) used within 3 weeks prior to enrollment; immunotherapy within 4 weeks; any palliative radiotherapy for non-target lesions used to relieve symptoms and traditional Chinese medicines indicated for the tumor (including Chinese patent medicine) within 2 weeks prior to enrollment.
  3. Use or intake of drugs or foods containing potent inhibitor or inducer of cytochrome P450 isozyme 3A4 (CYP3A4) within 14 days or 5 half-lives, whichever was the longer, prior to enrollment.
  4. Surgical operation (excluding aspiration biopsy) of main organs or a significant injury within 4 weeks prior to enrollment.
  5. Any unresolved toxicities from prior therapy greater than Grade 1 at the time of screening except alopecia.
  6. Inability to swallow the study medication, any seriously chronic gastrointestinal disorder, malabsorption syndrome or any other conditions with influence on gastrointestinal absorption.
  7. Active central nervous system metastases
  8. Previous or current interstitial lung disease, radiation pneumonitis which requires hormone therapy, or drug-related pneumonia, idiopathic interstitial pulmonary fibrosis identified in a baseline CT scan; uncontrolled massive pleural or pericardial effusion.
  9. Any active infection which has not been controlled at screening.
  10. Any serious cardiovascular disease.
  11. History of other serious systemic disease not suitable for clinical trial.
  12. Participation in other interventional clinical trial 4 weeks prior to enrollment or within 5 half-lives from the last dose of investigational product (whichever is longer).
  13. Known alcohol or drug dependence.
  14. Mental disorders or poor compliance.
  15. Previously received solid organ transplantation or hematopoietic stem cell transplantation.
  16. Females who are pregnant or breastfeeding.
  17. Known hypersensitivity to the active ingredients or excipients of the investigational product.
  18. Have any other primary malignant tumors within 3 years (except some low- risk cancers).

引自 ClinicalTrials.gov, NCT05168566, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT05168566,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT05168566